Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublocade for Opioid Use Disorder with Fentanyl Use
NCT03861338Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Mar 2019
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of buprenorphine in opioid use disorder (OUD), sponsored by New York State Psychiatric Institute. Primary endpoint: Sublocade Induction at 1 week. Started Mar 2019; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03861338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861338.